Literature DB >> 23354590

Viral therapy for pancreatic cancer: tackle the bad guys with poison.

Can Xu1, Haihang Li, Changqing Su, Zhaoshen Li.   

Abstract

Pancreatic cancer is one of the most devastating diseases with very poor prognosis. Only a small proportion is curable by surgical resection, whilst standard chemotherapy for patients with advanced disease has only modest effect with substantial toxicity. Therefore, there is an urgent need for the development of novel therapeutic approaches to improve the patient outcome. Recently the viral therapy is emerging as a novel effective therapeutic approach for cancer with the potential to selectively treat both primary tumor and metastatic lesions. This review provides an overview of the current status of viral treatment for pancreatic cancer, both in the laboratories and in clinical settings.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23354590     DOI: 10.1016/j.canlet.2013.01.035

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

1.  Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors.

Authors:  Marion Gayral; Hubert Lulka; Naima Hanoun; Coline Biollay; Janick Sèlves; Alix Vignolle-Vidoni; Hervé Berthommé; Pascal Trempat; Alberto L Epstein; Louis Buscail; Jean-Luc Béjot; Pierre Cordelier
Journal:  Hum Gene Ther       Date:  2015-01-19       Impact factor: 5.695

2.  Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus.

Authors:  S A Kaliberov; L N Kaliberova; D J Buchsbaum; D T Curiel
Journal:  Cancer Gene Ther       Date:  2014-06-06       Impact factor: 5.987

Review 3.  Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes.

Authors:  Marie Rouanet; Marine Lebrin; Fabian Gross; Barbara Bournet; Pierre Cordelier; Louis Buscail
Journal:  Int J Mol Sci       Date:  2017-06-08       Impact factor: 5.923

4.  Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma.

Authors:  Peter Duewell; Ebba Beller; Sabrina V Kirchleitner; Tina Adunka; Helene Bourhis; Jens Siveke; Doris Mayr; Sebastian Kobold; Stefan Endres; Max Schnurr
Journal:  Oncoimmunology       Date:  2015-04-14       Impact factor: 8.110

5.  Survivin promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in gastric cancer immunotherapy.

Authors:  Weiguo Wang; Weidan Ji; Huanzhang Hu; Juming Ma; Xiaoya Li; Weiqun Mei; Yang Xu; Huizhen Hu; Yan Yan; Qizhe Song; Zhigang Li; Changqing Su
Journal:  Oncotarget       Date:  2014-01-15

Review 6.  Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes.

Authors:  Alexander Malogolovkin; Nizami Gasanov; Alexander Egorov; Marianna Weener; Roman Ivanov; Alexander Karabelsky
Journal:  Viruses       Date:  2021-06-29       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.